The following table details the trading activities
(stock purchases, stock sales, and stock option exercises)
the Securities and Exchange Commission (SEC)
by insider Kumar Neil since year 2005.
The trader's CIK number is 1742485.
At the time of the last reporting, Kumar Neil was the Chief Executive Officer of Eidos Therapeutics, Inc. .
(stock ticker symbol EIDX).
See this page for all insider trading activities at Eidos Therapeutics, Inc. .
|Trade Date||Symbol||Company Name (Issuer)||Trade Type||Shares||Price ($)||Value ($)|
|2019-07-03||EIDX||Eidos Therapeutics, Inc.||Buy||882,353||29.90||26,383,237|
|2019-07-01||BBIO||Bridgebio Pharma, Inc.||Option Ex||8,952,428||.00||0|
|2019-05-24||EIDX||Eidos Therapeutics, Inc.||Buy||1,103,848||25.93||28,622,778|
|2018-06-22||EIDX||Eidos Therapeutics, Inc.||Buy||1,000,000||17.00||17,000,000|
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kumar Neil (Chief Executive Officer of Eidos Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.